ASN Kidney Week 2024
Surveyed physicians indicated that IgAN patients were referred to them late and not all potential cases had a timely biopsy.
C3 plays a key role in the formation of Gd-IgA1-containing IC with a nephritogenic capacity for IgAN.
Clinical improvement does not always reflect pathology, so renal biopsy may be needed to determine IgAN treatment efficacy.
Even when levels are below the current KDIGO threshold, proteinuria in IgAN indicates a risk of kidney failure.
Researchers found evidence that anti-mesangium IgA is involved in the pathogenesis of human IgAN.
Data from patient charts and surveys of nephrologists shed light on the future of individualizing treatment for IgAN.
Recent research reveals tolvaptan’s role in reducing hemodialysis initiation risk in ADPKD,
Contrary to recommendations, low-dose tolvaptan may be an option for refractory hyponatremia in cirrhosis.
A study examined physician confidence and barriers to prescription of tolvaptan for the management of ADPKD.
A study investigated whether treatment with difelikefalin and tolvaptan can protect against worsening of late-stage PKD.
ESSENTIAL assessed the safety and effectiveness of tolvaptan among patients in Korea with ADPKD and CKD stages 1 to 3.
Tolvaptan increased serum sodium without causing sodium overcorrection in syndrome of inappropriate antidiuresis.
A biopsy registry linked with administrative databases proved to be a practical way of studying IgAN at the population level.
Researchers identified six candidate loci that were significantly associated with IgA nephropathy prognosis.
The largest SnRNA-Seq profiling of IgAN kidney cells to date identified noteworthy cell-specific pathways in IgA nephropathy.
A study examined the impact loin pain has on IgAN patients' quality of life and strategies to manage the pain.
Analysis of single-nucleus data described heterogeneity in IgAN and found pathogenic alterations in the IgAN transcriptome.
A study examined the association between gross hematuria after COVID-19 vaccination and renal prognosis in IgAN patients.
Loss-of-function phenotypic screening with LEAPFROG-powered CRISPR-cas9 is likely to identify therapeutic targets for IgAN.
ARPCs isolated from urine of IgAN patients can form renal spheroids and tubular-like structures without external cytokines.
A study examined the association between circulating inflammatory proteins and disease progression in IgAN.
The phase 2 ENVISION trial examined the effect of sibeprenlimab on patients with IgAN.
Aquapheresis may provide an alternative for fluid removal in hypervolemia patients with sickle cell nephropathy.
Researchers reported on a patient with elevated 1,25-dihydroxyvitamin D with hypercalcemia and severe tophaceous gout.
A case report suggests treatment with intravenous pegloticase could help eGFR recovery in patients with uncontrolled gout.
A study examined gout incidence and risk among stage 3-5 CKD patients with asymptomatic hyperuricemia.
A study examined the prevalence, patient characteristics, and medical management of patients with gout and CKD.
A patient with gout experienced an increased risk of kidney stone formation after adopting a carnivore diet.
Researchers presented bone-related findings of a study on pegloticase use in kidney transplant recipients with gout.
Researchers explored an association between fluctuating uric acid levels and adverse prognoses in older adults with CKD.
A study examined the association between the prescription of ULT and the progression of kidney disease in patients with CKD.
Lupkynis for lupus nephritis is the focus of six accepted abstracts at the American Society of Nephrology Kidney Week 2024.
The American Society of Nephrology published the abstracts for Kidney Week 2024.
A late-breaking abstract at Kidney Week will report on a phase 3 trial of the ATEV in AV access for patients with ESRD.
Long-term results of a study of atacicept to treat IgA nephropathy (IgAN) will be presented at ASN Kidney Week.
ASN Kidney Week 2024 early programs take place October 23 and offer the chance to earn continuing education credits.
Three posters related to Unicycive's drug candidates for kidney diseases will be presented at ASN Kidney Week 2024.
Research on xanthine oxidase activity in polycystic kidney disease sponsored by XORTX will be presented at ASN Kidney Week.
The American Society of Nephrology (ASN) announced the plenary keynote speakers for its 2024 Kidney Week event.
Advertisement
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.